Hubbry Logo
Fosun PharmaFosun PharmaMain
Open search
Fosun Pharma
Community hub
Fosun Pharma
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Fosun Pharma
Fosun Pharma
Fosun Pharma
View on Wikipedia
from Wikipedia

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (trade name: Fosun Pharma) is a Chinese pharmaceutical company. It is mostly owned by Fosun International.[2]

Key Information

As of 2018, the A shares of the company is a constituent of SSE 180 Index as well as its sub-index SSE MidCap Index.[3] The company was ranked 1,840th in 2020 edition of the Forbes Global 2000, a list of top listed companies of the world.[4]

Key people

[edit]
  • Wu Yifang is the president and CEO of Fosun Pharma.[5]
  • Chen Qiyu is co-CEO of Fosun International and Chairman of Fosun Pharma.[6]

History

[edit]

Fosun Pharmaceutical is a listed company which started A share[7] initial public offering in 1998 and H share in 2012.[8] The English name of the company was initially known as Shanghai Fortune Industrial Joint-Stock Co., Ltd. (SFIC; Chinese: 上海复星实业股份有限公司),[9] but the transliteration of 复星 was later changed from Fortune to Fosun (as Fosun Industrial[10]), as well as changing the name from Industrial (Chinese: 实业) to Pharmaceutical (Chinese: 医药). The company also shorten the transliteration of the legal suffix 股份有限公司 from Joint-Stock Co., Ltd. to just Co., Ltd..

Shanghai Fortune Industrial Joint-Stock Co., Ltd. was incorporated in 1998, but its predecessor, Shanghai Fortune Industrial Company (Chinese: 上海复星实业公司) was incorporated in January 1994. The majority shareholders in December 1994 were Fosun High Technology (Chinese: 复星高科技) and its parent company Guangxin Technology (Chinese: 广信科技); Guangxin Technology was owned by Guo Guangchang, Liang Xinjun, Wang Qunbin and Fan Wei.[7][10]: 8 

In 2003 Fosun Pharmaceutical acquired 49% stake of Sinopharm Group (Chinese: 国药控股).[nb 1][10]: 30 [11] In 2008, a year before the initial public offering of Sinopharm Group, Fosun Pharmaceutical owned the direct parent company of Sinopharm Group, Sinopharm Industrial Investment (Chinese: 国药产业投资) instead; the majority owner of the joint venture was state-owned China National Pharmaceutical Group (Sinopharm).[nb 2][12][13][14]

An intermediate parent company of Fosun Pharma, Fosun International (parent company of Fosun High Technology), became a listed company in 2007.[15]

In 2014 Fosun Pharma was part of a consortium to acquire US-listed Chindex International, which owned private hospitals in mainland China.[16][17]

In 2016, according to the Financial Times, Fosun Pharmaceutical made the largest Indian corporate takeover by a Chinese company. The parties have now reached agreement that Fosun Pharma will acquire an approximate 74% stake in Gland Pharma for no more than US$1,091.30 million, including paying no more than US$25 million contingent consideration for Gland Pharma's Enoxaparin sales in the U.S. market.[18] Despite the offer was revised in 2017 to seek approval from Indian regulators.[19][20] In October 2017, the acquisition of 74% stake of Gland Pharma was completed.[1]: 35–36 

In September 2017, Israeli subsidiary Sisram Medical (parent company of Alma Lasers) was spin-off as a separate listed company on the Stock Exchange of Hong Kong.[21] As of 31 December 2017, Fosun Pharma owned Sisram Medical 52.83% shares.[22]

In October 2017 Fosun Pharmaceutical, via subsidiaries Fosun Pharmaceutical A.G. and Fosun Industrial[nb 3] bought Tridem Pharma, according to the Financial Times, "an Africa-focused French drug distributor", for not more than €63 million.[23][24] In January 2021, the company entered into a partnership with Insilico Medicine, to facilitate the latter's entry into the Chinese market.[25]

COVID-19

[edit]

Initial Responses

The company developed 2019-nCoV nucleic acid detection kit (PCR) which received emergency use authorization (EUA) from the FDA, was approved by the NMPA, and received CE certification from the European Union, as an in vitro diagnostic reagent.[26][27] By August 2020 Fosun Pharma donated medical masks, protective clothing, medical non-invasive ventilators, negative pressure ambulances, and other equipment and supplies valued at more than RMB 30 million to the epidemic area.[28]

COVID-19 Vaccine – BNT162b2

On 17 March 2020, BioNTech received a $135 million investment from Fosun in exchange for 1.58 million shares in BioNTech and the future development and marketing rights of the mRNA vaccine BNT162b2 in China.[29] Also, BioNTech announced a collaboration with Pfizer to scale-up manufacturing capacity to provide worldwide supply in response to the pandemic. BioNTech and Pfizer would commercialize the vaccine worldwide except in China, which was already covered by BioNTech's agreement with Fosun.[30]

Initial Investment in BioNTech and Early Testing

On 5 August, Fosun and BioNTech announced an initial Phase 1 trial in China that enrolled 144 volunteers to evaluate the safety and immunogenicity of BNT162b1.[31] On 4 November, Fosun announced it would stop further trials of BNT162b1, as results from trials in Germany, United States, and China all showed BNT162b2 to have a better safety profile.[32][33] BNT162b2 had missed an opportunity window to get tested in China, as another vaccine Fosun had started trials of BNT162b1 before trials data showed BNT162b2 as being the safer vaccine. Fosun's Chief Medical Officer Hui Aimin said that he didn't regret testing BNT162b1 without waiting for all the data. "For ordinary vaccines, it does not matter if you wait for a few days, or a month", Hui said. "But for COVID-19 vaccines, how many more people would have died had you waited just for one day?"[33]

Regulation and Commercialization

Fosun said it would instead focus on seeking Chinese regulatory approval for BioNTech's other candidate BNT162b2 which was already in Phase III trials by Pfizer since July. Fosun would apply for a bridge study on BNT162b2, designed to test if the large trial data done overseas could be extrapolated to the populace of China.[33]

In early August, Fosun and BioNTech signed an agreement with HKSE-listed Jacobson Pharma to supply 10 million doses of BNT162b2 to Hong Kong and Macau.[34]

On 6 November, Fosun was hopeful BNT162b2 could be available in China as soon as it became available in the United States and Europe.[35] On 20 November, Pfizer applied for emergency use approval from the Food and Drug Administration for BNT162b2.[36]

Shareholders

[edit]

Fosun Pharmaceutical had two classes of ordinary share: A shares which only traded in mainland China as well as H share which only traded in Hong Kong.

As of 31 December 2017, there was 2,011,190,000 number of A shares and 483,941,000 number of H shares, for a total of 2,495,131,000,[1]: 174  which Fosun International's wholly owned subsidiary, Fosun High Technology, owned 936,575,490 and 9,989,000 number of shares respectively.[1]: 59 

Fosun High Technology also once owned 23.45% of the convertible bond (SSE:100196) of Fosun Pharma in 2003.[10]: 6 

As of 31 December 2017, co-founder of Fosun High Technology and now co-owner of the parent company of Fosun International, Guo Guangchang and Wang Qunbin, still served as non-executive directors of Fosun Pharmaceutical.[1]: 2  As of 31 July 2019, the market capitalization of the H share of Fosun Pharma was HK$12,943,004,725.[37]

Footnotes

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Fosun Pharma

View on Grokipedia
from Grokipedia
Fosun Pharmaceutical (Group) Co., Ltd., known as Fosun Pharma (stock codes: 600196.SH, 02196.HK), is a Chinese multinational healthcare founded in 1994 and headquartered in . It operates as an innovation-driven group focused on the research, development, , and distribution of pharmaceuticals, medical devices, diagnostics, and healthcare services, with core therapeutic areas including , , and metabolic disorders. Fosun Pharma has pursued global expansion through acquisitions, partnerships, and R&D investments, establishing operations in pharmaceuticals manufacturing and advanced technologies such as antibody drugs and cell therapies across more than 30 countries. The company has recorded significant revenue growth from innovative products, reaching over RMB 3.7 billion in the first half of 2024 alone, and reported total operating revenue of RMB 41.07 billion for the full year. Despite these advancements, Fosun Pharma encountered a major in when whistleblowers alleged that a in systematically falsified active pharmaceutical ingredient production and testing data while bribing regulators to conceal deficiencies, prompting investigations into compliance practices.

Company Overview

Founding and Evolution

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., known as Fosun Pharma, was founded in in , , as an innovation-driven pharmaceutical and healthcare entity initially focused on addressing domestic healthcare gaps through manufacturing and research. It originated as a within the of Limited, a conglomerate established in 1992 by five Fudan University graduates, including , who identified opportunities in 's emerging pharmaceutical sector amid post-reform . The company's early operations emphasized generic drugs and basic R&D to meet local demand, leveraging 's rapid and healthcare needs in the mid-1990s. Fosun Pharma achieved its initial public listing on the in August 1998 under stock code 600196, enabling capital raising for expansion amid China's state-driven growth. By the early , it co-founded Sinopharm Group in 2003, China's largest pharmaceutical distributor, which bolstered its and commercialization capabilities while navigating regulatory reforms under the . This period marked a shift from mere production to integrated services, including medical devices and diagnostics. The company's evolution accelerated in the with a secondary listing on the in October 2012 (stock code 02196), facilitating international financing and global outreach. Adopting the "4IN" —encompassing innovation, internationalization, intelligentization, and integration—Fosun Pharma built a global R&D ecosystem targeting , , and advanced therapies like antibody-drug conjugates, expanding operations to the U.S., , , , and through acquisitions and partnerships. This progression transformed it from a China-centric manufacturer into a multinational group with over 40,000 employees by 2024, prioritizing proprietary drug pipelines over generics in response to pressures and market maturation.

Corporate Structure and Ownership

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., operating as Fosun Pharma, functions as a overseeing subsidiaries engaged in pharmaceutical , , , and distribution across domestic and international markets. The group's includes key entities such as Fosun Industrial, which manages diagnostics and medical devices; Fosun Pharma Global, focusing on international expansion; and strategic investments like a 49% stake in Sinopharm Medicine Holding, a major Chinese distributor and retailer. This decentralized model enables segment-specific operations while centralizing strategic oversight from headquarters in . Fosun International Limited maintains controlling ownership of Fosun Pharma, holding 36.64% of shares as of June 15, 2025, positioning it as the dominant shareholder with influence over major decisions. The company is publicly traded on the under ticker 600196 and the under 2196.HK, resulting in a dispersed free float beyond the controlling stake. Overall, the top 25 shareholders control approximately 48% of equity, with institutional investors for about 12% and the remainder held by retail and other investors.
Major ShareholderOwnership PercentageNotes
Fosun International Limited36.64%Controlling interest as of June 15, 2025
China Merchants Fund Management Co., Ltd.1.08%Institutional holder
, Inc.0.99%International institutional holder as of September 29, 2025
This composition reflects Fosun Pharma's integration within the broader Fosun ecosystem, where leverages its stake to align pharmaceutical operations with conglomerate-wide strategies in and industrial sectors. No single entity beyond holds a blocking minority, facilitating agile amid public listing requirements.

Core Business Segments

Fosun Pharma's core business segments encompass , medical devices, , and healthcare services, which form the foundation of its direct operations across the healthcare . These segments align with the company's strategy to integrate research, development, production, and service delivery, supported by investments in global partnerships and acquisitions. Pharmaceutical manufacturing serves as the primary segment, generating RMB 28,924 million in in and comprising sub-areas such as innovator drugs, mature pharmaceutical products, and active pharmaceutical ingredients (APIs). Innovator drugs emphasize R&D in —including solid tumors and hematologic malignancies—and immune-inflammatory disorders, with over 80 ongoing projects leveraging technologies like antibody-drug conjugates, cell therapies, and . Mature products and APIs focus on established formulations and raw materials production to support generic and branded offerings. The medical devices and instruments segment involves the development and distribution of high-value equipment, targeting areas such as diagnostics and surgical tools, with an emphasis on innovative and imported technologies to expand in and internationally. Medical and include in-vitro diagnostics, systems, and preventive services, integrating data-driven solutions for early detection and chronic . Healthcare services cover operations, networks, and integrated care models, often through subsidiaries providing specialized treatments and patient . Additionally, Fosun Pharma holds stakes in and retail via Sinopharm Group Co., Ltd., facilitating broader access, though this operates indirectly as a interest rather than a direct segment.

Leadership and Governance

Key Executives and Decision-Makers

Chen Yuqing serves as Executive Director and Chairman of Fosun Pharma, appointed to the role on May 1, 2025, succeeding Wu Yifang. Aged 50, he holds a in engineering from and joined the Fosun Group after brief academic experience as a teacher at Shanghai University's School of Materials from 1997 to 1999. In this capacity, Chen has emphasized strategic adjustments, including exiting non-controlling stakes and underperforming assets to streamline operations, as stated during an August 27, 2025, performance briefing. Liu Yi is the and President, having succeeded Wen Deyong in the CEO role effective June 24, 2025, while also serving as Chairman and CEO of the Fosun MedTech Division. Aged 50, Liu possesses a doctorate in from and brings over 20 years of expertise in , , and medical technology, including prior roles as senior vice president of Fosun Pharma and Chairman of Sisram Medical Ltd. He oversees broader executive functions and the MedTech segment, focusing on innovation in medical devices and diagnostics. Co-Presidents manage specialized divisions: Li Jing leads as CEO of the Established Medicines and Supply Division, handling production and distribution of generic and branded drugs. Xingli Wang serves as Co-Chairman and Co-CEO of the Innovative Medicines Division alongside CEO of the Global R&D Center, directing research pipelines and novel therapeutics development. Wenjie Zhang acts as Co-CEO of the Innovative Medicines Division and CEO of Fosun Pharma USA, bridging international expansion in biologics and partnerships. Guan Xiaohui holds the position of and Co-Chairman, contributing to strategic oversight. Wen Deyong, and Vice Chairman, previously served as CEO before transitioning in June 2025, retaining influence on governance. Wang Kexin is an involved in board-level decisions. These leaders, aligned with Fosun International's conglomerate structure, drive decisions on acquisitions, R&D investments, and global , though their effectiveness is shaped by parent company priorities under .

Board Composition and Influence

The Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. consists of 12 members as of December 31, 2024, comprising executive directors, non-executive directors, four independent non-executive directors with expertise in areas such as , , pharmaceuticals, technology licensing, and commercialization, and two female directors. The independent directors provide specialized oversight to ensure balanced separate from influence. Prominent executive directors include Chen Yuqing, who serves as Chairman; Guan Xiaohui as Co-Chairman; Wen Deyong as Vice Chairman; and Wang Kexin as an , all appointed to steer operational and strategic directions. These roles reflect continuity in leadership tied to the Fosun conglomerate's structure, with board changes announced as recently as September 30, 2025, incorporating a mix of executive, non-executive, independent, and employee representatives to enhance diverse input. The board exerts influence through five specialized committees—Strategy, , Nominating, and Appraisal, and Environment, Social and Governance—each chaired by distinct members to distribute authority and address key governance areas like , , and . This structure supports independent operations from controlling shareholders via defined terms of reference, special meetings for independent directors, and adherence to the company's and board diversity policy. As a , the board's strategic influence aligns closely with Ltd., which holds a controlling 36.64% stake as of June 15, 2025, prioritizing group-wide objectives such as international acquisitions, innovation pipelines, and in pharmaceuticals and medtech. This affiliation shapes board priorities toward conglomerate synergies, though formal mechanisms aim to mitigate potential conflicts by emphasizing duties to all shareholders.

Historical Milestones

Establishment and Early Growth (1990s–2000s)

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., commonly known as Fosun Pharma, was established in 1994 in , , as an entity focused on pharmaceuticals within the broader Fosun Group framework. The founding aligned with China's emerging healthcare needs, positioning the company to develop and manufacture drugs amid rapid economic reforms and increasing demand for medical products. Initial operations emphasized building a domestic presence in pharmaceutical production, leveraging local market opportunities in a sector previously dominated by state-owned enterprises. In 1998, Fosun Pharma achieved a significant by listing on the (stock code: 600196), which provided capital for expansion and marked it as one of the early private healthcare firms to access public markets in . This IPO enabled investments in manufacturing capabilities and product pipelines, fostering steady revenue growth through generic drugs and basic healthcare offerings during the late 1990s. The 2000s saw Fosun Pharma's early diversification beyond core pharmaceuticals into areas like medical devices and initial international outreach, entering markets in the United States, , , , and to broaden its and distribution. By the decade's end, strategic moves such as a 2009 acquisition of an 11.18% stake in Chindex Medical for approximately $22 million signaled growing ambitions in cross-border healthcare investments. This period laid the groundwork for scaling operations, with a focus on integrating innovation into domestic strengths while navigating regulatory and competitive landscapes in China's evolving .

Major Expansions and Acquisitions (2010s)

In the , Fosun Pharma pursued aggressive and innovation through strategic acquisitions and expansions, aiming to bolster its capabilities in biopharmaceuticals, medical devices, and healthcare services outside . This period marked a shift toward overseas targets, particularly in the United States, , and , to acquire advanced technologies and established market presence, with cumulative deal values exceeding $1.6 billion across 17 transactions by mid-2016. The strategy emphasized injecting capital into high-growth segments like antibody-drug conjugates and generic injectables, while leveraging partnerships to mitigate regulatory hurdles in foreign markets. A pivotal early move was the 2010 acquisition of a 17.45% stake in U.S.-listed Chindex International Inc. for $14 million, which operated premium hospitals under the United Family Healthcare brand in . This investment laid the foundation for deeper integration, culminating in when Fosun Pharma, alongside TPG Capital, privatized Chindex in a sweetened deal valued at $461 million, with Fosun contributing up to $223.6 million to secure majority control and an additional $45 million for a 30% stake in its medical subsidiary. The transaction expanded Fosun's footprint in high-end healthcare services, targeting affluent urban consumers in with Western-style facilities. In innovation, Fosun Pharma joined a consortium in 2015—including HOPU Investments, China Everbright Limited's healthcare fund, and WuXi PharmaTech—to acquire Ambrx Inc., a San Diego-based clinical-stage firm specializing in and antibody-drug conjugates. The deal, closed in the second quarter of 2015, provided access to Ambrx's proprietary platform for site-specific bioconjugates, enhancing Fosun's R&D pipeline in and other therapeutics. The decade's largest transaction was the 2017 completion of a 74% stake acquisition in India's Gland Pharma Ltd. for $1.09 billion, following an initial 2016 agreement valued at up to $1.26 billion for an 86% stake (later adjusted after management participation). , a leading injectable generics producer with a U.S. FDA-approved facility, represented the biggest Indian acquisition by a Chinese firm at the time, strengthening Fosun's global for sterile products and export capabilities to regulated markets like the U.S. and . These deals collectively diversified Fosun Pharma's portfolio beyond domestic generics, though they increased exposure to foreign regulatory scrutiny and integration challenges.

COVID-19 Era Developments (2020–2022)

In March 2020, Fosun Pharma entered a strategic collaboration with to co-develop and commercialize mRNA-based vaccines, including BNT162, exclusively in , , , and ; Fosun handled clinical trials, manufacturing, and commercialization in these regions using BioNTech's technology platform. On November 16, 2020, Chinese regulators approved the initiation of phase I/II trials for BNT162b2 (later Comirnaty) in . By December 2022, Fosun and supplied approximately 11,500 doses to for targeted vaccination and sold over 15 million doses in , , and during 2022. Fosun Diagnostics, a , developed the Fosun RT-PCR Detection Kit, which received U.S. FDA on April 17, 2020, for qualitative detection of nucleic acids in respiratory specimens; the kit was the first in its category to submit a complete clinical application data report. The product obtained in and certifications in the U.S., , , and over 10 other countries, enabling global sales. In 2021, Fosun Pharma expanded its response by deploying resources for prevention, testing, and treatment products, including distribution centers to ensure stability. These efforts contributed to revenue growth amid the pandemic; Fosun Pharma reported 2021 revenues boosted by test kit exports and related activities, with overall group revenue reaching RMB 39 billion, up from prior years. In the first half of 2022, revenues hit RMB 21.34 billion, a 25.88% year-over-year increase, partly from vaccine and diagnostic sales, while full-year 2022 revenues totaled RMB 43.95 billion, up 12.66%. In March 2022, Fosun signed a sublicense with the to produce generic (a Paxlovid component) for low- and middle-income countries, enhancing access to antiviral treatment.

Operations and Innovation

Pharmaceutical Manufacturing and Supply Chain

Fosun Pharma maintains its primary pharmaceutical manufacturing operations in , operating 13 production sites across provinces including , , , , and , equipped with 46 production lines, all compliant with Good Manufacturing Practices (GMP). In 2019, the company acquired a pharmaceutical factory in , Province, from GlaxoSmithKline for approximately ¥250 million ($36 million), gaining rights to produce generic versions of Epivir (lamivudine). These facilities support production of innovative small-molecule drugs, biologics, and generics across therapeutic areas such as , , and . To extend its manufacturing footprint beyond , Fosun Pharma entered a partnership with the (IFC) in June 2023 to develop a greenfield pharmaceutical production facility and distribution hub near , Côte d'Ivoire, through its subsidiary Guilin Pharmaceutical. Upon completion, the plant is projected to achieve an annual capacity of five billion tablets, positioning it as Côte d'Ivoire's largest such facility and aiding localization of drug production in to meet regional demand and reduce import reliance. Fosun Pharma's supply chain management emphasizes optimization for efficiency and sustainability, contributing to positive operating cash flows, such as RMB 4.48 billion in 2024. In May 2025, it joined the Pharmaceutical Supply Chain Initiative (PSCI) as an associate member, aligning with global standards for ethical sourcing, environmental responsibility, and worker welfare in pharmaceutical supply networks. The company's efforts include risk mitigation through diversified sourcing and compliance audits, though its heavy reliance on Chinese suppliers exposes it to potential disruptions from domestic regulatory changes or geopolitical tensions.

Research and Development Pipeline

Fosun Pharma's research and development encompasses over 70 projects as of August 2025, including 23 self-developed small-molecule innovator drugs, 19 self-developed innovative biologics, 21 in-licensed innovator drugs, and 12 self-developed biosimilars, with a focus on first-in-class (FIC) and best-in-class (BIC) candidates across , , and other areas. The company advances its through internal development, licensing agreements, and partnerships, prioritizing high-value indications such as solid tumors and immune-mediated diseases. In , key candidates include FH1701 (Fu Mai Ning®), a MEK1/2 inhibitor targeting in adults and children, adult histiocytic tumors, pediatric , low-grade , and extracranial arteriovenous malformations, with s approved in the United States. FCN-437c (Fu Tuo Ning®), a CDK4/6 inhibitor for second-line and first-line , has also received U.S. approval. Additional oncology assets feature SAF-189s, an for non-small cell with U.S. trial approval; FCN-338, a inhibitor for myeloid hematological malignancies; XS-03 combination therapy, a inhibitor for advanced solid tumors with RAS mutations; and XS-02, a CHK1 inhibitor for advanced solid tumors. In July 2025, Luvometinib Tablets advanced to Phase 3 trials for pediatric low-grade in . Beyond , the pipeline includes and respiratory candidates such as AC-201, a selective oral small-molecule TYK2/JAK1 inhibitor for moderate-to-severe plaque , which completed Phase 2 trials meeting primary and secondary endpoints with favorable safety; Fosun Pharma secured exclusive development, manufacturing, and commercialization rights in in August 2025. XS-04 targets IRAK4/BTK for hematomas, while XH-S004, a DPP-1 inhibitor, addresses non-cystic bronchiectasis and . FXS6837 is in Phase 1 in for immune regulation-related diseases. Strategic partnerships bolster the pipeline, including a June 2025 collaboration with Teva for TEV-56278, an investigational anti-PD1-IL2 therapy in early-stage immuno-oncology development, and an August 2025 $645 million licensing deal with Expedition Therapeutics for a respiratory involving joint global trials. Fosun Pharma integrates via its PharmaID platform to enhance R&D efficiency, supporting target identification and decision-making in . In 2025 interim results, the company reported in-licensing AR1001, FXB0871, and HLX701 to expand its portfolio, alongside initiating clinical trials for 18 innovative products or biosimilars by indications. These efforts align with Fosun's "4IN" strategy emphasizing amid challenges in global regulatory scrutiny for Chinese biopharma firms.

Medical Devices, Diagnostics, and Services

Fosun Pharma maintains a diversified portfolio in medical devices through its FOSUNMEDTECH platform, which integrates domestic and international subsidiaries to deliver solutions in medical aesthetics, respiratory health, and professional medical technologies. The platform emphasizes digital and intelligent innovations to support industrial upgrading and device localization, targeting global markets while leveraging local operational expertise. A key subsidiary, Sisram Medical—majority-owned by Fosun Pharma and listed on the since September 19, 2017—focuses on aesthetic and wellness devices, stemming from the 2013 acquisition of Alma Lasers Ltd. Sisram expanded its presence in July 2023 by acquiring Photonmed, establishing direct operations for energy-based aesthetic treatments, and reported annual revenue growth in 2024 driven by new product launches and . In diagnostics, Fosun Pharma operates via Fosun Diagnostics (Shanghai) Co., Ltd., established in 1989, which develops products across clinical chemistry, immunoassays, molecular diagnostics, microbiology, and point-of-care testing (POCT). The company has constructed automated production bases, including the Baoshan R&D and manufacturing facilities approved for in vitro diagnostics to address antiviral and antifungal needs. Recent advancements incorporate AI, with Fosun Aitrox providing imaging analysis tools for radiology, pathology, and ultrasound, enhancing diagnostic accuracy and efficiency in clinical settings as of February 2025. Fosun Diagnostics has secured multiple approvals from China's (NMPA), supporting expanded domestic and international deployment. Healthcare services form another pillar, with Fosun Pharma investing in high-end facilities in coastal cities and specialized to integrate diagnostics and treatment. In December 2015, it committed RMB 400 million to establish Shanghai Fosun in , expanding its regional footprint. Through Fosun Health, the group deploys smart healthcare solutions linked to , fostering comprehensive service ecosystems. Internationally, a April 2025 partnership with Fakeeh Care Group in advances tele-diagnostics, cell and therapies, and AI-driven platforms. These efforts align with Fosun Pharma's strategy to prioritize high-value devices and services, contributing to segment revenue growth amid global expansion.

Financial Performance

Fosun Pharma's expanded rapidly from RMB 30.163 billion in 2020 to RMB 38.86 billion in 2021 and RMB 43.952 billion in 2022, reflecting a exceeding 20% during this period, primarily fueled by heightened demand for vaccines and diagnostics developed in collaboration with . Following the peak in 2022, total contracted as pandemic-related sales subsided, reaching approximately RMB 41.4 billion in 2023 before edging down 0.8% to RMB 41.07 billion in 2024. Excluding products, underlying growth persisted, with a 5.31% year-on-year rise in the first half of 2024 and 5.74% for the first nine months. In the first half of 2025, fell to RMB 19.514 billion amid softer domestic demand and competitive pressures in generic drugs, though overseas contributions reached RMB 5.478 billion, or 28% of the total. Profitability demonstrated resilience and gradual improvement despite revenue volatility, with net profit margins attributable to shareholders climbing from 7.05% in 2023 to 8.59% in 2024, supported by a strategic pivot to higher-value innovative drugs—which accounted for over 20% of —and stringent cost management, including a 2.45 enhancement in gross margins net of selling expenses. This margin expansion offset normalizing COVID contributions, yielding a 16% increase in net profit attributable to shareholders for 2024. surged 31% year-on-year in 2024, underscoring improved from efficient utilization. By mid-2025, despite revenue contraction, net profit rose year-on-year, driven by administrative expense reductions and sustained overseas expansion, where grew to represent 28% of the half-year total.
YearRevenue (RMB billion)Net Profit Margin (%)
202030.16-
202138.86-
202243.95-
202341.47.05
202441.078.59

Debt, Investments, and Market Position

As of March 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. reported total debt of CN¥33.6 billion, with a of approximately 55.8% based on shareholder equity of CN¥60.3 billion. This level reflects ongoing efforts to manage leverage amid expansion, including repayments of matured bonds by its parent , which handled RMB11.1 billion equivalent in public bonds during 2024. Fosun Pharma has pursued strategic investments through acquisitions and partnerships to bolster its innovation pipeline and global footprint. In September 2025, it acquired Antejin Biotech, a Chengdu-based firm specializing in bacterial development and pharmaceutical services. Earlier, it completed the acquisition of 95.20% of Alma Lasers for $221.63 million to enhance its medical and high-value device capabilities. In a , Fosun Pharma partnered to acquire U.S.-based Ambrx Biopharma, focusing on bio-conjugates for and other therapies, integrating external R&D with internal resources. These moves align with a diversified model incorporating licensing, fund investments, and co-development for first-in-class and best-in-class drugs. In the , Fosun Pharma holds a mid-tier position among Chinese firms, with 2024 operating revenue of RMB41.07 billion, including RMB11.3 billion from overseas markets, driven by innovative drugs and devices. Its stood at approximately HK$83.69 billion for H-shares as of late October 2025, complementing A-share valuation, positioning it as a key player in , , and medical devices within while expanding internationally. growth of 5.74% year-over-year through September 2024 (excluding COVID products) underscores resilience, though it trails global giants in scale.

Controversies and Regulatory Challenges

Data Integrity and Quality Control Issues

In February 2017, the U.S. (FDA) issued a warning letter to Pharma Research Institute Co., Ltd., a of Fosun Pharma, following an inspection that identified significant violations of current (cGMP) regulations for active pharmaceutical ingredients (APIs). The letter highlighted deficiencies, including failures to ensure the accuracy and reliability of , with evidence of potential omissions, alterations, deletions, and record destruction. It required the firm to conduct a comprehensive assessment of the scope of these issues, implement corrective actions, and submit a remediation plan, noting that inadequate controls undermined the reliability of records and manufacturing processes. In August 2018, whistleblowers alleged widespread data falsification at Fosun Pharma's Research Institute Pharmaceutical Co., Ltd. (CPRI), another API manufacturing unit, claiming employees were directed to fabricate large volumes of production records, testing data, and stability reports to meet regulatory and sales targets. These accusations included of local regulators to conceal violations and predated a November 2017 FDA pre-approval inspection, which had already flagged ongoing cGMP deviations, including lapses similar to those in the 2017 warning. The disclosures prompted an unannounced spot check by the Food and Drug Administration on August 23, 2018, and contributed to a sharp decline in Fosun Pharma's stock price. Fosun Pharma responded by denying the claims, attributing some data inconsistencies to operational errors rather than systemic , and affirming that internal audits and mechanisms were in place. The company committed to cooperating with investigations and enhancing quality controls, though no formal FDA actions beyond the prior warning were publicly detailed in relation to the 2018 allegations. These incidents reflect broader challenges in Chinese API manufacturing, where data integrity issues have drawn international regulatory , but Fosun Pharma maintained operations without reported bans or shutdowns tied to these events.

Financial and Governance Scrutiny

In September 2022, , the parent conglomerate of Fosun Pharma, faced heightened investor scrutiny amid reports that Chinese regulators instructed major banks and state-owned enterprises to assess their financial exposure to the group, amid concerns over maturing bonds totaling approximately $8 billion by year-end. This pressure contributed to a slide in Fosun Pharma's shares and bonds, reflecting broader market worries about the group's leverage and , though Fosun Pharma maintained that its operations remained stable and denied any direct regulatory into its financials. By end-2023, 's parent-level debt had decreased to RMB 88.8 billion following divestments, yet persistent debt servicing demands continued to cloud performance, including Fosun Pharma's, which reported revenue declines from mature drugs and COVID-related products in 2023. A notable incident occurred in August 2018 when Chinese regulators conducted an unannounced spot check on Fosun Pharma's subsidiary, Chongqing Pharmaceutical Research Institute, prompting a 10% drop in the company's shares amid allegations of irregularities. An employee whistleblower claimed the unit fabricated active pharmaceutical ingredients (APIs), production reports, and other documentation, leading Fosun Pharma to initiate an internal probe while affirming cooperation with authorities. These events underscored potential lapses in financial reporting and supply chain controls, though no formal charges or penalties against Fosun Pharma itself were publicly detailed beyond the investigation. Governance scrutiny has centered on leadership opacity and internal controls, exemplified by the 2015 temporary detention of Fosun co-founder and chairman , which authorities described as assistance in a personal affairs probe but triggered widespread concerns over the unpredictability of China's legal system for private executives. Similar rumors in of Guo's disappearance again pressured Fosun Pharma's stock, highlighting vulnerabilities in executive succession and transparency. In response to such risks, Fosun Pharma established a strategic in June 2025 to oversee mid- and long-term investments and enhance governance rigor, aiming to mitigate exposure from aggressive expansion strategies inherited from the parent group. Despite self-reported ESG advancements and awards, external assessments have flagged ongoing controversies with reputational and financial implications tied to these historical episodes.

Ties to Chinese State and Geopolitical Risks

Fosun Pharma, as a subsidiary of the privately held conglomerate, operates in an environment where the (CCP) maintains pervasive influence over private enterprises through mechanisms such as embedded party committees, regulatory oversight, and alignment with national strategic priorities. This influence is evident in Fosun's collaborations with local governments, including a March 2024 partnership with authorities to launch a 5 billion yuan (about US$700 million) fund targeting investments in areas like cellular and . Such initiatives support Beijing's broader pharmaceutical reforms aimed at lowering medical costs and fostering innovation, positioning Fosun as a key contributor to state-endorsed industry development. In 2015, Fosun International chairman Guangchang's temporary detention by authorities underscored the vulnerability of even prominent private firms to abrupt state intervention, amid a pattern of CCP crackdowns on leaders perceived as straying from party directives. Geopolitically, Fosun Pharma encounters substantial risks from U.S.- frictions, which intensify scrutiny of its global expansions and dependencies. Trade tensions prompted Fosun to reassess U.S. acquisitions in 2019, as reviews by the Committee on Foreign Investment in the United States (CFIUS) heightened barriers to cross-border deals involving sensitive technologies. In response, the company has pivoted toward domestic consolidation, exemplified by its September 2024 acquisition of the Fosun Kite joint venture—originally formed with U.S.-based —for $27 million, enhancing local capabilities amid decoupling trends. These dynamics expose Fosun to potential sanctions, export controls on dual-use pharma tech, and disruptions in international partnerships, particularly as Western governments seek to mitigate reliance on Chinese manufacturing for critical health products. Similar challenges arose in 2017 when Sino-Indian border disputes jeopardized Fosun's proposed acquisition of an Indian pharma asset, illustrating how bilateral geopolitical strains can derail overseas strategies. Overall, Fosun's ties to state priorities amplify exposure to policy shifts in , while global tensions threaten revenue from foreign markets and technology access.

Recent Developments and Future Outlook

Technological Advancements like AI Integration

Fosun Pharma has integrated (AI) into its drug processes through the self-developed PharmAID platform, launched in February 2025, which supports efficient innovation by applying AI in target identification, compound screening, and optimization. The platform leverages algorithms to analyze vast datasets, accelerating decision-making in R&D pipelines and reducing timelines for candidate selection. In its 2025 interim results, the company reported deepening this AI strategy to build an integrated digital system spanning R&D, , and , aiming to enhance overall . A key collaboration involves Insilico Medicine, announced on January 11, 2022, focusing on AI-driven for four undisclosed biological targets, with Fosun Pharma handling downstream development and . This partnership utilizes Insilico's generative AI models for novel molecule design, demonstrating Fosun's approach to outsourcing computational expertise while retaining control over clinical advancement. By April 2025, Fosun outlined plans to expand PharmAID into a broader public platform for AI-assisted drug R&D, intending to foster industry-wide innovation through shared computational tools. Beyond , Fosun applies AI in via its Fosun Aitrox subsidiary, which deploys for diagnostic accuracy in areas like tumor detection, and in precision medicine for personalized treatment predictions. The company has also pioneered (AR) navigation in minimally invasive , integrating it with AI for real-time guidance to improve procedural precision. In healthcare services, Fosun Health Cloud's (HIS) incorporated a DeepSeek AI assistant to analyze patient records and generate diagnostic recommendations, enhancing clinical workflows as of recent implementations. These advancements reflect Fosun's strategic emphasis on AI to address R&D bottlenecks, though their long-term impact depends on validation through clinical outcomes and regulatory approvals.

Global Expansion Efforts

Fosun Pharma has expanded internationally primarily through acquisitions of overseas companies, strategic partnerships, and licensing deals for innovative drugs, focusing on markets in , , and emerging regions like and . In the first half of 2025, overseas revenue reached RMB 5 billion, reflecting growth in these efforts, while full-year 2024 overseas revenue stood at RMB 11.3 billion, comprising 27% of . Key acquisitions include Breas Medical AB, a Swedish ventilator manufacturer, completed in March 2017 to bolster medical device capabilities in . In 2021, Fosun Pharma jointly acquired Ambrx Biopharma, a U.S.-based firm specializing in for protein therapeutics, which has since collaborated with global players like Bristol-Myers Squibb, Merck, and . Another notable purchase was Alma Lasers, an Israel-headquartered aesthetic company, aimed at supporting its global in laser technologies. These moves have integrated foreign R&D and manufacturing expertise into Fosun's portfolio, with operations spanning over 35 countries. Partnerships and licensing have accelerated drug commercialization abroad. Subsidiary Henlius Biotech has out-licensed products to more than 20 international firms, including deals for biologics like serplulimab, which gained approvals in the , UK, and by 2025 and launched in over 30 countries. In June 2025, Fosun Pharma partnered with Teva Pharmaceutical Industries to develop TEV-56278, an anti-PD1-IL2 therapy for cancer, targeting U.S. and global markets. Additionally, in August 2025, its small-molecule drug XH-S004 for autoimmune diseases secured an overseas license with potential value up to $645 million, underscoring in-licensing strategies for innovative pipelines. Fosun Pharma has further facilitated U.S. entry through collaborations with entities like MAP Pharmaceuticals for pain therapies and Fakeeh Care Group for cell and gene treatments in 2025. These initiatives have positioned Fosun Pharma among China's leading pharmaceutical exporters, with innovative drugs contributing over RMB 4.3 billion in H1 2025 revenue, much of it from international channels. However, expansion faces challenges from geopolitical tensions and regulatory hurdles in Western markets, though the company continues to prioritize GMP certifications from the U.S. and for subsidiaries like Wanbang and Pharma.

References

  1. https://www.fosunpharma.com/en/about/profile.html
  2. https://www.fosunpharma.com/en/about/
  3. https://www.fosunpharma.com/en/business/
  4. https://www.fosunpharma.com/en/content/details37_15782.html
  5. https://www.prnewswire.com/news-releases/fosun-pharma-announces-2024-annual-results-302411485.html
  6. https://www.fiercepharma.com/manufacturing/fosun-pharma-massively-fakes-api-production-data-and-bribes-regulators-whistle-blower
  7. https://pestel-analysis.com/blogs/brief-history/fosunpharma
  8. https://swotanalysisexample.com/blogs/brief-history/fosunpharma-brief-history
  9. https://pharmaboardroom.com/directory/fosun-pharma/page/32/
  10. https://thebusiness-insight.com/ceo-fosun-pharma-wu-yifang/
  11. https://www.fosunpharma.com/en/content/details37_11256.html
  12. https://disclosures.ifc.org/project-detail/SPI/24812/fosun-pharma
  13. https://ir.fosun.com/en/investor-relations/fosun-ecosystem/corporate-structure/
  14. https://pestel-analysis.com/blogs/owners/fosunpharma
  15. https://www.marketscreener.com/quote/stock/SHANGHAI-FOSUN-PHARMACEUT-6548924/company/
  16. https://www.moomoo.com/news/post/59791918/retail-investors-among-shanghai-fosun-pharmaceutical-group-co-ltd-s
  17. https://za.investing.com/equities/fosun-pharma-ownership
  18. https://simplywall.st/stocks/de/pharmaceuticals-biotech/fra-08hh/shanghai-fosun-pharmaceutical-group-shares/ownership
  19. https://www.fosunpharma.com/en/business/pharmaceutical.html
  20. https://www.reuters.com/markets/companies/600196.SS/
  21. http://media.drugdu.com/ddu-news/fosun-pharma-changes-its-leader-taking-over-from-wu-yifang-chen-yuqing-becomes-the-chairman-of-fosun-pharma.html
  22. https://www.henlius.com/en/board-of-directors.html
  23. https://news.futunn.com/en/post/61231525/fosun-pharma-chairman-chen-yuqing-exiting-non-controlling-and-difficult
  24. https://news.futunn.com/en/post/58404223/fosun-pharma-names-ceo
  25. https://theorg.com/org/sisram-medical-ltd/org-chart/liu-yi
  26. https://www.fosunpharma.com/en/about/team_2.html
  27. https://fosunpharmausa.com/our-leadership/
  28. https://www.fosunpharma.com/en/about/team.html
  29. https://en.fosun.com/about/team.html
  30. https://www.fosunpharma.com/en/investor/govern.html
  31. https://www.tipranks.com/news/company-announcements/shanghai-fosun-pharmaceutical-announces-board-composition-and-committee-roles-2
  32. https://ir.fosun.com/en/about-us/who-we-are/
  33. https://pharmaboardroom.com/directory/fosun-pharma/
  34. http://www.chinadaily.com.cn/bizchina/2009-11/19/content_9010171.htm
  35. https://m.economictimes.com/industry/healthcare/biotech/pharmaceuticals/fosun-leads-the-race-to-buy-gland-pharma-with-1-27-billion-bid/articleshow/52611608.cms
  36. http://www.uschina.org/articles/chindex-to-be-acquired-by-fosun-pharma-and-tpg-capital-for-369-million/
  37. https://www.reuters.com/article/business/fosun-pharma-tpg-agree-to-buy-chindex-in-sweetened-461-mln-deal-idUSL3N0NE0DZ/
  38. https://www.fosunpharma.com/en/content/details37_11158.html
  39. https://www.wuxiapptec.com/news/wuxi-news/3171
  40. https://m.economictimes.com/industry/healthcare/biotech/pharmaceuticals/fosun-pharma-acquires-74-stake-in-gland-pharma-for-1-09-billion/articleshow/60941486.cms
  41. https://www.fosunpharma.com/en/content/details37_11333.html
  42. https://www.spglobal.com/marketintelligence/en/mi/country-industry-forecasting.html?id=10659117898
  43. https://investors.biontech.de/news-releases/news-release-details/biontech-and-fosun-pharma-form-covid-19-vaccine-strategic
  44. https://fosunpharmausa.com/wp-content/uploads/2022/06/Fosun-Pharma-2022-Barnding-PPT_ENG_V2022041580-KW-26May2022.pdf
  45. https://biontechse.gcs-web.com/news-releases/news-release-details/biontech-and-fosun-pharma-receive-approval-commence-covid-19
  46. https://finance.yahoo.com/news/biontech-fosun-pharma-covid-19-110000221.html
  47. https://ir.fosun.com/media/s3cabzf0/2022-annual-results-en.pdf
  48. https://www.fda.gov/media/137120/download
  49. https://www.fosunpharma.com/en/content/details37_11652.html
  50. https://www.fosunpharma.com/en/content/details37_11648.html
  51. https://fosunpharmausa.com/fosun-pharma-2021-annual-results-announcement/
  52. https://www.fosunpharma.com/en/Upload/File/202207/6c84098bdea64906aa1268c65fd3ade5.pdf
  53. https://www.fosunpharma.com/en/content/details37_11858.html
  54. https://www.fosunpharma.com/en/content/details37_12275.html
  55. https://medicinespatentpool.org/story-post/fosun-pharmas-global-impact-expanding-access-to-covid-19-treatments-and-beyond-through-voluntary-licensing-with-mpp
  56. https://disclosures.ifc.org/project-detail/AS-ESRS/24812/fosun-pharma
  57. https://www.fiercepharma.com/manufacturing/fosun-snatches-gsk-plant-china-along-rights-to-make-epivir-generic
  58. https://www.pharmaceutical-technology.com/news/fosun-pharma-ifc-drug-manufacturing/
  59. https://www.ifc.org/en/pressroom/2023/ifc-supports-fosun-pharmas-construction-of-largest-pharmaceutica
  60. https://www.fosunpharma.com/en/content/details262_16607.html
  61. https://en.fosun.com/content/details46_5046.html
  62. https://www.fosunpharma.com/en/innovate/pipeline.html
  63. https://www.prnewswire.com/news-releases/fosun-pharma-announces-2025-interim-results-302538922.html
  64. https://www.fosunpharma.com/en/content/details37_16858.html
  65. https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2025/Teva-and-Fosun-Pharma-Enter-into-a-Strategic-Partnership-to-Develop-Novel-Anti-PD1-IL2-Therapy-TEV-56278-in-Immuno-Oncology/default.aspx
  66. https://firstwordpharma.com/story/5988187
  67. https://www.biospace.com/press-releases/fosun-pharmaceutical-deeply-embraces-ai-self-developed-pharmaid-decision-intelligence-platform-boosts-efficient-innovation
  68. https://ir.fosun.com/media/gx4imrvo/en-2025-interim-results-presentation.pdf
  69. https://www.fosunpharma.com/en/content/details37_16824.html
  70. https://www.fosunpharma.com/en/business/appliances.html
  71. https://sisram-medical.com/our-story/
  72. https://www.fosunpharma.com/en/content/details37_11332.html
  73. https://www.prnewswire.com/apac/news-releases/alma-a-sisram-medical-company-is-establishing-a-direct-operation-in-china-after-completing-the-acquisition-of-photonmed-301868748.html
  74. https://en.fosun.com/content/details46_5269.html
  75. https://www.fosundiagnostics.com/en/web/about.do
  76. https://www.fosunpharma.com/en/business/diagnosis.html
  77. https://www.fosunpharma.com/en/content/details37_11233.html
  78. https://www.prnewswire.com/news-releases/fosun-pharmaceutical-deeply-embraces-ai-self-developed-pharmaid-decision-intelligence-platform-boosts-efficient-innovation-302377891.html
  79. https://www.fosunam.com/details.php?id=172
  80. http://endmalaria.org/partner/fosun-pharma-shanghai-fosun-pharmaceutical%25EF%25BC%2588group%25EF%25BC%2589co-ltd
  81. https://www.fosunpharma.com/en/content/details37_11277.html
  82. https://www.fosunhealth.com/en/
  83. https://en.fosun.com/content/details46_5393.html
  84. https://www.biospace.com/press-releases/fosun-pharma-announces-2024-annual-results
  85. https://www.fosunpharma.com/en/Upload/File/202207/ee369e611e2d46358dab357fc00313ce.pdf
  86. https://ir.fosun.com/media/2emlk1c3/fosun-2021ar-fn-en.pdf
  87. https://www.prnewswire.com/news-releases/fosun-pharma-announces-2022-annual-results-achieved-steady-growth-with-revenue-from-record-high-innovative-products-and-global-commercialization-capability-improvement-301783100.html
  88. https://www.fosunpharma.com/en/content/details37_16210.html
  89. https://firstwordpharma.com/story/5889930
  90. https://www.biospace.com/press-releases/fosun-pharma-announces-2024q3-financial-results
  91. https://www.fosunpharma.com/en/Upload/File/202504/2f67efdd85dd40848411f8622f8a350c.pdf
  92. https://www.ainvest.com/news/decoding-fosun-pharma-profit-surge-revenue-decline-strategic-contradiction-sustainable-turnaround-2508/
  93. https://www.linkedin.com/posts/pandayu_the-following-is-a-summary-of-the-financial-activity-7376428994902216704-I8TU
  94. https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2196/shanghai-fosun-pharmaceutical-group-shares/health
  95. https://www.moomoo.com/news/post/57412147/shanghai-fosun-pharmaceutical-group-shse-600196-has-a-pretty-healthy
  96. https://firstwordpharma.com/story/5946222
  97. https://tracxn.com/d/acquisitions/acquisitions-by-fosun-pharmaceutical/__W9erzfleh2OlmR9DysiFPgMjBkw5FZ9j9IZN51oc0p8
  98. https://www.fosunpharma.com/en/content/details37_11047.html
  99. https://firstwordpharma.com/story/5946816
  100. https://finance.yahoo.com/quote/2196.HK/
  101. https://www.prnewswire.com/news-releases/fosun-pharma-announces-2024q3-financial-results-302290914.html
  102. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/chongqing-pharma-research-institute-co-ltd-515080-02142017
  103. https://www.reuters.com/article/business/healthcare-pharmaceuticals/shanghai-fosun-pharmas-unit-receives-warning-letter-from-us-fda-idUSL3N1GE42D/
  104. https://www.yicaiglobal.com/news/fosun-pharma-makes-fake-apis-production-reports-employee-says
  105. https://www.reuters.com/article/business/healthcare-pharmaceuticals/chinas-fosun-pharma-stock-tumbles-after-regulators-spot-check-on-subsidiary-idUSL8N1VM090/
  106. https://www.fosunpharma.com/uploads/2018083182521.pdf
  107. https://cen.acs.org/articles/95/i11/FDA-warns-Wockhardt-Fosun.html
  108. https://www.bloomberg.com/news/articles/2022-09-13/china-tells-banks-soes-to-report-exposure-to-conglomerate-fosun
  109. https://www.theguardian.com/business/2022/sep/13/china-banks-fosun-thomas-cook-club-med
  110. https://www.bloomberg.com/news/articles/2022-09-14/chinese-conglomerate-fosun-under-scrutiny-as-bonds-shares-slide
  111. https://www.globaltimes.cn/page/202209/1275216.shtml
  112. https://thebambooworks.com/debt-pressures-cast-cloud-over-fosun-pharma-results/
  113. https://www.bondsupermart.com/bsm/article-detail/with-fosun-international-s-weight-loss-actions-could-it-resolve-its-debt-crisis-RCMS_291361
  114. https://www.yicaiglobal.com/news/fosun-is-probing-report-of-pharma-unit-fraud-chairman-says
  115. https://www.pharmaceutical-technology.com/comment/chinese-pharma-manufacturing/
  116. https://www.reuters.com/article/business/china-probe-concerns-billionaire-fosun-founders-personal-affairs-idUSKBN0TW09O/
  117. https://www.afr.com/world/chinas-methods-under-scrutiny-as-fosun-founder-reemerges-20151214-gln9eu
  118. https://www.fiercepharma.com/pharma-asia/fosun-stock-tumbles-over-rumors-chairman-disappearance-again
  119. https://www.tipranks.com/news/company-announcements/shanghai-fosun-pharma-strengthens-strategic-oversight-with-new-committee
  120. https://www.spglobal.com/sustainable1/en/scores/results?cid=4533438
  121. https://www.csis.org/analysis/ccp-inc-portugal-chinas-investments-financial-services-and-reach-chinese-communist-party
  122. https://www.gisreportsonline.com/r/chinese-stock-markets/
  123. https://www.scmp.com/business/china-business/article/3255387/fosun-pharma-joins-shenzhen-government-raise-us700-million-healthcare-fund-invest-biomedicine
  124. https://www.fiercepharma.com/financials/fosun-group-attempts-to-explain-as-high-profile-chief-detained-by-china-authorities
  125. https://www.economist.com/business/2022/11/03/fosuns-big-asset-sale-marks-the-end-of-an-era-in-chinese-business
  126. https://www.bloomberg.com/news/articles/2019-05-30/trade-tensions-mean-china-s-fosun-is-rethinking-u-s-deals
  127. https://www.bioworld.com/articles/712672-fosun-acquiring-fosun-kite-joint-venture-in-china-for-27m
  128. https://matrixbcg.com/products/fosunpharma-pestle-analysis
  129. https://www.congress.gov/crs-product/R46304
  130. https://www.scmp.com/business/banking-finance/article/2104989/will-fosuns-deal-go-ahead-amid-sino-indian-spat
  131. https://asiatimes.com/2025/05/high-and-rising-political-price-of-chinas-uk-investments/
  132. https://www.fosunpharma.com/en/content/details37_16098.html
  133. https://www.prnewswire.com/news-releases/fosun-pharma-and-insilico-medicine-announce-a-strategic-ai-driven-drug-discovery-and-development-collaboration-to-jointly-advance-multiple-targets-301457569.html
  134. https://www.biopharminternational.com/view/fosun-pharma-and-insilico-medicine-partner-on-drug-discovery-and-development-using-artificial-intelligence
  135. https://en.fosun.com/content/details46_5283.html
  136. https://news.futunn.com/en/post/53215300/fosun-pharma-02196-deeply-embraces-ai-with-its-self-developed
  137. https://www.fosunhealth.com/en/news/page-2.html
  138. https://en.fosun.com/content/details46_5434.html
  139. https://www.fosunpharma.com/en/content/details37_11322.html
  140. https://ir.fosun.com/en/about-us/global-industries/
  141. https://www.stocktitan.net/news/TEVA/teva-and-fosun-pharma-enter-into-a-strategic-partnership-to-develop-2z7863prd7uq.html
  142. https://www.prnewswire.com/news-releases/fosun-pharmas-small-molecule-innovative-drug-xh-s004-achieves-overseas-licensing-for-a-potential-total-of-645-million-302527024.html
  143. https://fosunpharmausa.com/news_filter/2025/
  144. https://www.fosunpharma.com/en/Upload/File/202504/170b9bf773f545068c2601053c9a1fcc.pdf
Add your contribution
Related Hubs
User Avatar
No comments yet.